Quantcast

Industry news that matters to you.  Learn more

Thermo Fisher Scientific Opens New Biomarker Translational Center

Thermo Fisher Scientific Inc., the world leader in serving science, today announced at the Human Proteome Organization (HUPO) 2011 World Congress the establishment of a new Biomarker Translational Center (BT Center). The purpose of the BT Center is to accelerate mass spectrometry (MS)-based biomarker discovery research and its translation into the development of routine clinical assays for subsequent commercialization. Based in Cambridge, Mass., the BT Center combines advanced expertise from across Thermo Fisher including its B·R·A·H·M·S product line and the team at the Biomarkers Research Initiatives in Mass Spectrometry (BRIMS) Center.

Thermo Fisher Scientific BRIMS Center and MGH Announce Initial Findings of Stroke Research

Thermo Fisher Scientific recently announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center in collaboration with Massachusetts General Hospital (MGH), Harvard University. Strokes are the leading cause of serious long-term disability in the U.S. The research was previewed at the Mass Spectrometry Applications to the Clinical Lab (MSACL) conference in San Diego last month.

Thermo Fisher, Proteome Sciences Form Biomarker Alliance

Thermo Fisher Scientific today said that it will collaborate with Proteome Sciences to develop quantitative proteomic workflows for biomarker discovery and validation.

Thermo Fisher Scientific and Intrinsic Bioprobes Announce Alliance in Mass Spectrometric Immunoassay Workflow Development

Thermo Fisher Scientific, Inc., the world leader in serving science, and Intrinsic Bioprobes (IBI) Inc., today announced an alliance to co-develop and market a mass spectrometry solution that will enable researchers to perform quantitative, high-throughput, high-resolution protein biomarker assays. The solution couples the specificity of immunoenrichment with the sensitivity and quantitative capability of mass spectrometry to provide researchers with a more complete, higher-resolution view of the proteome. Initially, via an exclusive reseller agreement, the solution will be applied to the detection of human parathyroid hormone (PTH) and its variants, which may be useful as biomarkers for bone diseases and diseases of the endocrine system.